Privo Technologies Receives U.S. FDA Orphan Drug Designation ...Middle East

PEABODY, Mass., Aug. 12, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo") announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Privo's PRV platform delivery of cisplatin for the treatment of carcinoma in situ (CIS) of the...

Hence then, the article about privo technologies receives u s fda orphan drug designation was published today ( Friday 12/08/2022 - 06:37 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Privo Technologies Receives U.S. FDA Orphan Drug Designation )

Also on site :

• Crocs’ Platform Sandals With 'Squishy Cloud Comfort' and 'Excellent Arch Support' Are 60% Off for Amazon Prime Day
• Slate Auto says each $24,950 electric pickup truck will be profitable as it aims to be cash-flow positive next year
• 1990s Nirvana Song Ranked the Best Hidden Track of the Decade Was Never Listed on the Album